47 results on '"Manceñido N"'
Search Results
2. P905 Predictive pharmacogenetic risk of pancreatitis in Inflammatory Bowel Disease patients treated with thiopurines: a case-control study from the ENEIDA registry
- Author
-
Guerra Marina, I, primary, Barros, F, additional, Chaparro, M, additional, Benítez, J M, additional, Martín Arranz, M D, additional, de Francisco, R, additional, Piqueras, M, additional, de Castro, L, additional, Carbajo, A Y, additional, Bermejo, F, additional, Mínguez, M, additional, Gutiérrez, A, additional, Mesonero, F, additional, Cañete, F, additional, González-Muñoza, C, additional, Calvo, M, additional, Sicilia, B, additional, Alfambra, E, additional, Tardillo, C A, additional, Rivero, M, additional, Lucendo, A J, additional, Bujanda, L, additional, Van Domselaar, M, additional, Almela, P, additional, Ramos, L, additional, Fernández Sánchez, M, additional, Hinojosa, E, additional, Verdejo, C, additional, Gimenez, A, additional, Rodríguez-Lago, I, additional, Manceñido, N, additional, Pérez Calle, J L, additional, Moreno, M D P, additional, Delgado-Guillena, P G, additional, Antolín, B, additional, Ramírez de la Piscina, P, additional, Casanova, M J, additional, Carracedo, Á, additional, Domènech, E, additional, and Gisbert, J P, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
- Author
-
Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I, Gisbert JP, Mesonero F, Benítez O, Taxonera C, Ponferrada-Díaz Á, Piqueras M, Lucendo AJ, Caballol B, Mañosa M, Martínez-Montiel P, Bosca-Watts M, Gordillo J, Bujanda L, Manceñido N, Martínez-Pérez T, López A, Rodríguez-Gutiérrez C, García-López S, Vega P, Rivero M, Melcarne L, Calvo M, Iborra M, Barreiro de-Acosta M, Sicilia B, Barrio J, Pérez JL, Busquets D, Pérez-Martínez I, Navarro-Llavat M, Hernández V, Argüelles-Arias F, Ramírez Esteso F, Meijide S, Ramos L, Gomollón F, Muñoz F, Suris G, de Zarate JO, Huguet JM, Llaó J, García-Sepulcre MF, Sierra M, Durà M, Estrecha S, Fuentes Coronel A, Hinojosa E, Olivan L, Iglesias E, Gutiérrez A, Varela P, Rull N, Gilabert P, Hernández-Camba A, Brotons A, Ginard D, Sesé E, Carpio D, Aceituno M, Cabriada JL, González-Lama Y, Jiménez L, Chaparro M, López-San Román A, Alba C, Plaza-Santos R, Mena R, Tamarit-Sebastián S, Ricart E, Calafat M, Olivares S, Navarro P, Bertoletti F, Alonso-Galán H, Pajares R, Olcina P, Manzano P, Domènech E, Esteve M, On Behalf Of The Eneida Registry Of Geteccu, [Zabana Y] Hospital Universitari Mútua Terrassa, Terrassa, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. [Marín-Jiménez I] Hospital Gregorio Marañón, Madrid, Spain. [Rodríguez-Lago I] Gastroenterology Department, Hospital Universitario de Galdakao, Galdakao, Spain. Biocruces Bizkaia Health Research Institute, Galdakao, Spain. [Vera I] Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Martín-Arranz MD] Hospital Universitario La Paz, Madrid, Spain. [Guerra I] Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. Instituto de Investigación Hospital Universitario La Paz (IdiPaz), Madrid, Spain. [Piqueras M, Mena R] Servei de Digestologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain, Consorci Sanitari de Terrassa, and Universidad de Sevilla. Departamento de Medicina
- Subjects
index ,Pronòstic mèdic ,Risk factors in diseases ,COVID-19 (Malaltia) ,Article ,Inflammatory bowel disease ,Comorbiditat ,inflammatory bowel disease ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Epidemiology and Biostatistics::Epidemiology::Health-Disease Process::Comorbidity [PUBLIC HEALTH] ,Factors de risc en les malalties ,SARS-CoV-2 ,COVID-19 ,determinants ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,General Medicine ,Prognosis ,enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades intestinales::enfermedad inflamatoria intestinal [ENFERMEDADES] ,infection ,epidemiología y bioestadística::epidemiología::proceso salud-enfermedad::comorbilidad [SALUD PÚBLICA] ,Medicine ,Digestive System Diseases::Gastrointestinal Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases [DISEASES] ,Intestins - Inflamació - Abstract
We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged >= 60 years (OR 7.1, 95% CI: 1.8-27 and 4.5, 95% CI: 1.3-15.9), while having >= 2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3-11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD. This study is funded by the Carlos III Health Institute (COV20/00227: Co-IP Dra. Maria Esteve and Dra. Yamile Zabana), FEDER (Fondo Europeo de Desarrollo Regional) and supported by GETECCU. The ENEIDA Registry of GETECCU is supported by Takeda, Pfizer, Galapagos, AbbVie and Biogen.
- Published
- 2022
4. Surgery Due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an Ecco Confer Multicentre Case Series (Scar Study)
- Author
-
Chaparro M, Kunovský L, Aguas M, Livne M, Rivière P, Shitrit AB, Myrelid P, Arroyo M, Barreiro-de Acosta M, Bautista M, Biancone L, Avni Biron I, Boysen T, Carpio D, Castro B, Dragoni G, Ellul P, Holubar SD, de Jorge MÁ, Leo E, Manceñido N, Moens A, Molnár T, Ramírez de la Piscina P, Ricanek P, Sebkova L, Sempere L, Teich N, Gisbert JP, Julsgaard M, and ECCO CONFER taskforce
- Subjects
Crohn’s disease ,surgery ,gestation ,pregnancy ,Inflammatory bowel disease ,ulcerative colitis - Abstract
AIMS: i) To evaluate the evolution of pregnancies and offspring after inflammatory bowel disease (IBD) surgery during pregnancy; and ii) to describe the indications, the surgical techniques, and the frequency of caesarean section concomitant to surgery. METHODS: Patients operated on due to IBD during pregnancy after 1998 were included. Participating clinicians were asked to review their databases to identify cases. Data on patients' demographics, IBD characteristics, medical treatments, IBD activity, pregnancy outcomes, surgery, delivery, foetal and maternal outcomes, were recorded. RESULTS: Forty-four IBD patients were included, 75% had Crohn's disease. Eighteen percent of the surgeries were performed in the 1 st trimester, 55% in the 2 nd, and 27% in the 3 rd trimester. One patient had complications during surgery, and 27% had postsurgical complications. No patient died. Seventy percent of deliveries were carried out by caesarean section. There were 40 newborns alive and 4 miscarriages/stillbirths (1 in the 1 st, 2 in the 2 nd, and 1 in the 3 rd trimester): 2 occurred during surgery, and another 2 occurred 2 weeks after surgery. Fourteen percent of the surgeries during the 2 nd trimester and 64% of those in the 3 rd trimester ended up with a simultaneous cesarean section or vaginal delivery. Of the 40 newborns, 61% were premature, and 47% had low birth weight; 42% of newborns needed hospitalisation (25% in the intensive care unit). CONCLUSIONS: IBD surgery during pregnancy remains an extremely serious situation. Therefore, surgical management should be performed in a multidisciplinary team, involving gastroenterologists, colorectal surgeons, obstetricians and neonatal specialists.
- Published
- 2022
5. P487 Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study)
- Author
-
Chaparro, M, primary, Aguas, M, additional, Livne, M, additional, Rivière, P, additional, Bar-Gil Shitrit, A, additional, Myrelid, P, additional, Arroyo, M, additional, Barreiro-de Acosta, M, additional, Bautista, M, additional, Biancone, L, additional, Biron, I A, additional, Boysen, T, additional, Carpio, D, additional, Castro, B, additional, Dragoni, G, additional, Ellul, P, additional, Holubar, S D, additional, de Jorge, M Á, additional, Leo, E, additional, Manceñido, N, additional, Moens, A, additional, Ramírez de la Piscina, P, additional, Ricanek, P, additional, Sebkona, L, additional, Sempere, L, additional, Teich, N, additional, Gisbert, J P, additional, and Julsgaard, M, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group
- Author
-
Fernández-Bañares, F., Casanova, M. J., Arguedas, Y., Beltrán, B., Busquets, D., Fernández, J. M., Fernández-Salazar, L., García-Planella, E., Guagnozzi, D., Lucendo, A. J., Manceñido, N., Marín-Jiménez, I., Montoro, M., Piqueras, M., Robles, V., Ruiz-Cerulla, A., and Gisbert, J. P.
- Published
- 2016
- Full Text
- View/download PDF
7. P262 Effectiveness and safety of ustekinumab in elderly patients: Real world evidence from ENEIDA registry
- Author
-
Casas Deza, D, primary, Lamuela Calvo, L J, additional, Arbonés Mainar, J M, additional, Ricart, E, additional, Gisbert, J P, additional, Rivero Tirado, M, additional, Sanchez Rodríguez, E, additional, Sicilia, B, additional, Gutierrez Casbas, A, additional, Merino Ochoa, O, additional, Márquez, L, additional, Laredo de la Torre, V, additional, Martin Arranz, M D, additional, Lopez Serrano, P, additional, Riestra Menéndez, S, additional, Gonzalez Muñoza, C, additional, de Castro Parga, L, additional, Calvo Moya, M, additional, Garcia Alonso, J, additional, Esteve, M, additional, Iborra Colomino, M, additional, Dura Gil, M, additional, Barreiro de Acosta, M, additional, Lorente Poyatos, R, additional, Manceñido, N, additional, Caballo, B, additional, Calafat, M, additional, Rodríguez Lago, I, additional, Guardiola Capo, J, additional, Morales Alvarado, V J, additional, Tardillo, C, additional, Bujanda, L, additional, Muñoz Nuñez, J F, additional, Ber Nieto, Y, additional, Bermejo, F, additional, Chaparro, M, additional, Almela, P, additional, Navarro, M, additional, Domènech, E, additional, and García López, S, additional
- Published
- 2021
- Full Text
- View/download PDF
8. DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study
- Author
-
Zabana Abdo, Y, primary, Marín-Jiménez, I, additional, Rodríguez-Lago, I, additional, Vera, I, additional, Martín, M D, additional, Guerra, I, additional, Gisbert, J P, additional, Mesonero, F, additional, Benítez, O, additional, Taxonera, C, additional, Ponferrada-Díaz, Á, additional, Piqueras, M, additional, Lucendo, A, additional, Caballol, B, additional, Mañosa, M, additional, Martínez-Montiel, P, additional, Bosca-Watts, M, additional, Gordillo, J, additional, Bujanda, L, additional, Manceñido, N, additional, Martínez-Pérez, T, additional, López, A, additional, Rodríguez, C, additional, García-López, S, additional, Vega, P, additional, Rivero, M, additional, Melcarne, L, additional, Calvo, M, additional, Iborra, M, additional, Barreiro-de Acosta, M, additional, Arias, L, additional, Barrio, J, additional, Pérez, J L, additional, Busquets, D, additional, Pérez-Martínez, I, additional, Navarro-Llavat, M, additional, Hernández, V, additional, Argüelles-Arias, F, additional, Domènech, E, additional, and Esteve, M, additional
- Published
- 2021
- Full Text
- View/download PDF
9. P357 Long-term outcomes of biologic therapy in Crohn’s disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU
- Author
-
Rodríguez-Lago, I, primary, Fernández-Clotet, A, additional, Mesonero, F, additional, García-Alonso, F J, additional, Casanova, M J, additional, Fernández-de la Varga, M, additional, Cañete, F, additional, de Castro, L, additional, Gutiérrez, A, additional, Sicilia, B, additional, Cano, V, additional, Merino, O, additional, Riestra, S, additional, González-Partida, I, additional, Surís, G, additional, Torrealba, L, additional, Ferreiro-Iglesias, R, additional, Castro, B, additional, Márquez, L, additional, Sobrino, A, additional, Elorza, A, additional, Calvet, X, additional, Varela, P, additional, Betoré, E, additional, Bujanda, L, additional, Lario, L, additional, Manceñido, N, additional, García-Sepulcre, M, additional, Iglesias, E, additional, Rodríguez, C, additional, Piqueras, M, additional, Ferrer Rosique, J Á, additional, Lucendo, A, additional, Benítez, O, additional, García, M, additional, Olivares, D, additional, González-Muñoza, C, additional, Cabriada, J L, additional, Domènech, E, additional, and Barreiro-de Acosta, M, additional
- Published
- 2021
- Full Text
- View/download PDF
10. P476 Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry
- Author
-
Chaparro, M, primary, Garre, A, additional, Iborra, M, additional, Sierra, M, additional, Barreiro-de Acosta, M, additional, Fernández-Clotet, A, additional, de Castro, L, additional, Boscá-Watts, M, additional, Casanova, M J, additional, López-García, A, additional, Lorente, R, additional, Rodríguez, C, additional, Carbajo, A Y, additional, Arroyo, M T, additional, Gutiérrez, A, additional, Hinojosa, J, additional, Martínez-Pérez, T, additional, Villoria, A, additional, Bermejo, F, additional, Busquets, D, additional, Camps, B, additional, Cañete, F, additional, Manceñido, N, additional, Monfort, D, additional, Navarro-Llavat, M, additional, Pérez-Calle, J L, additional, Ramos, L, additional, Rivero, M, additional, Angueira, T, additional, Camo, P, additional, Carpio, D, additional, García-de-la-Filia, I, additional, González-Muñoza, C, additional, Hernández, L, additional, Huguet, J M, additional, Morales, V J, additional, Sicilia, B, additional, Vega, P, additional, Domènech, E, additional, and Gisbert, J P, additional
- Published
- 2021
- Full Text
- View/download PDF
11. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients
- Author
-
González-Lama, Y., Bermejo, F., López-Sanromán, A., García-Sánchez, V., Esteve, M., Cabriada, J. L., McNicholl, A. G., Pajares, R., Casellas, F., Merino, O., Carpio, D., Vera, M. I., Muñoz, C., Benito, L. M., Bujanda, L., García-Fernández, F. J., Ricart, E., Ginard, D., Velasco, M., Carneros, J. A., Manceñido, N., Calvo, M., Algaba, A., Froilan, C., Cara, C., Maté, J., Abreu, L., and Gisbert, J. P.
- Published
- 2011
- Full Text
- View/download PDF
12. OP29 Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry
- Author
-
Chaparro, M, primary, Garre, A, additional, Mesonero, F, additional, Rodríguez, C, additional, Barreiro-de Acosta, M, additional, Martínez-Cadilla, J, additional, Arroyo, M T, additional, Manceñido, N, additional, Sierra-Ausín, M, additional, Vera-Mendoza, I, additional, Casanova, M J, additional, Nos, P, additional, González-Muñoza, C, additional, Martínez, T, additional, Boscá-Watts, M, additional, Busquets, D, additional, Calafat, M, additional, Girona, E, additional, Llaó, J, additional, Martín-Arranz, M D, additional, Piqueras, M, additional, Ramos, L, additional, Suis, G, additional, Bermejo, F, additional, Carbajo, A Y, additional, Casas-Deza, D, additional, Fernández-Clotet, A, additional, García, M J, additional, Ginard, D, additional, Gutiérrez-Casbas, A, additional, Hernández-Villalba, L, additional, Lucendo, A J, additional, Márquez, L, additional, Merino-Ochoa, O, additional, Rancel, F J, additional, Taxonera, C, additional, López Sanromán, A, additional, Rubio, S, additional, Domènech, E, additional, and Gisbert, J P, additional
- Published
- 2020
- Full Text
- View/download PDF
13. P434 Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from Eneida Registry
- Author
-
Chaparro, M, primary, Garre, A, additional, Iborra, M, additional, Barreiro-de Acosta, M, additional, Casanova, M J, additional, De Castro, L, additional, Fernández-Clotet, A, additional, Hinojosa, J, additional, Boscá-Watts, M, additional, Busquets, D, additional, López-García, A, additional, Lorente, R, additional, Manceñido, N, additional, Martínez, T, additional, Monfort, D, additional, Pérez-Calle, J L, additional, Villoria, A, additional, Angueira, T, additional, Bermejo, F, additional, Carbajo, A Y, additional, Carpio, D, additional, González-Muñoza, C, additional, Gomollón, F, additional, Huguet, J M, additional, Rivero, M, additional, Iglesias-Flores, E, additional, Sierra, M, additional, Hernández-Villalba, L, additional, Domènech, E, additional, and Gisbert, J P, additional
- Published
- 2020
- Full Text
- View/download PDF
14. P681 Efficacy of vedolizumab for the prevention of postoperative recurrence in Crohn’s disease: Data from clinical practice from the ENEIDA registry
- Author
-
Mañosa Ciria, M, primary, Hinojosa, E, additional, Carbajo, A, additional, Castro, J, additional, Manceñido, N, additional, Calvo, M, additional, Núñez Alonso, A, additional, P Gisbert, J, additional, Nos, P, additional, Guardiola, J, additional, Sainz, E, additional, Sánchez-Rodríguez, E, additional, Cañete, F, additional, Calafat, M, additional, and Domènech, E, additional
- Published
- 2020
- Full Text
- View/download PDF
15. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients
- Author
-
Barreiro-de Acosta, M, Marin-Jimenez, I, Panadero, A, Guardiola, J, Cañas M, Gobbo Montoya M, Modino, Y, Alcain, G, Bosca-Watts, MM, Calvet, X, Casellas, F, Chaparro, M, Fernández Salazar L, Ferreiro-Iglesias, R, Ginard, D, Iborra, M, Manceñido N, Mañosa M, Merino, O, Rivero, M, Roncero, O, Sempere, L, Vega, P, Zabana, Y, Minguez, M, Nos, P, and Gisbert, JP
- Subjects
Crohn's disease ,Psychological problems ,Ulcerative colitis ,Depression ,Anxiety ,Clinical practice guidelines ,Inflammatory bowel disease - Abstract
Aims: To establish recommendations for the management of psychological problems affecting patients with inflammatory bowel disease (IBD). Methods: A meeting of a group of IBD experts made up of doctors, psychologists, nurses and patient representatives was held. The following were presented: 1) Results of a previous focal group, 2) Results of doctor and patient surveys, 3) Results of a systematic review of tools for detecting anxiety and depression. A guided discussion was then held about the most important psychological and emotional problems associated with IBD, appropriate referral criteria and situations to be avoided. The validated instrument most applicable to clinical practice was selected. A recommendations document and a Delphi survey were designed. The survey was sent to the group and to a scientific committee of the GETECCU group in order to establish the level of agreement with these recommendations. Results: Fifteen recommendations were established linked to 3 key processes: 1) What steps should be taken to identify psychological problems at an IBD appointment; 2) What are the criteria for referring patients to a mental health specialist; 3) How to approach psychological problems. Conclusions: Resources should be made available to healthcare professionals so that they can treat these problems during consultations, identify the disorders which could affect the clinical course of the disease and determine their impact on the patient's life in order that these can be treated and followed up by the most suitable professional. These recommendations could serve as a basis for redesigning IBD services or processes and as justification for the training of healthcare personnel. (C) 2017 Elsevier Espana, S.L.U. All rights reserved.
- Published
- 2018
16. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study
- Author
-
Chaparro, M, primary, Verreth, A, additional, Lobaton, T, additional, Gravito-Soares, E, additional, Julsgaard, M, additional, Savarino, E, additional, Magro, F, additional, Biron, Avni I, additional, Lopez-Serrano, P, additional, Casanova, M J, additional, Gompertz, M, additional, Vitor, S, additional, Arroyo, M, additional, Pugliese, D, additional, Zabana, Y, additional, Vicente, R, additional, Aguas, M, additional, Shitrit, Bar-Gil A, additional, Gutierrez, A, additional, Doherty, G A, additional, Fernandez-Salazar, L, additional, Cadilla, Martínez J, additional, Huguet, J M, additional, O'Toole, A, additional, Stasi, E, additional, Marcos, Manceñido N, additional, Villoria, A, additional, Karmiris, K, additional, Rahier, J F, additional, Rodriguez, C, additional, Palomares, Diz-Lois M, additional, Fiorino, G, additional, Benitez, J M, additional, Principi, M, additional, Naftali, T, additional, Taxonera, C, additional, Mantzaris, G, additional, Sebkova, L, additional, Iade, B, additional, Lissner, D, additional, Bradley, Ferrer I, additional, Roman, Lopez-San A, additional, Marin-Jimenez, I, additional, Merino, O, additional, Sierra, M, additional, Van Domselaar, M, additional, Caprioli, F, additional, Guerra, I, additional, Peixe, P, additional, Piqueras, M, additional, Rodriguez-Lago, I, additional, Ber, Y, additional, van Hoeve, K, additional, Torres, P, additional, Gravito-Soares, M, additional, Rudbeck-Resdal, D, additional, Bartolo, O, additional, Peixoto, A, additional, Martin, G, additional, Armuzzi, A, additional, Garre, A, additional, Donday, M G, additional, de Carpi, Martín F J, additional, and Gisbert, J P, additional
- Published
- 2018
- Full Text
- View/download PDF
17. Diffuse cavernous hemangioma of the rectum: an atypical cause of rectal bleeding
- Author
-
Hervías, D., Turrión, J. P., Herrera, M., Navajas León, J., Pajares Villarroya, R., Manceñido, N., Castillo, P., and Segura, J.M.
- Subjects
Cavernous hemangioma ,Rectal bleeding ,Resonancia magnética nuclear ,Recto ,Rectorragias ,Rectum ,Colonoscopia ,Colonoscopy ,Hemangioma cavernoso ,MRI - Abstract
Objective: cavernous hemangioma of the rectosigmoid colon is a rare disease, with no more than 200 cases reported in the literature. The rectosigmoid is the most common site of this disease in the gastrointestinal tract. Case report: we report the case of a 31-year-old male with recurrent episodes of rectal bleeding, who was finally diagnosed of diffuse cavernous hemangioma of the rectum. The tumor, of 12 x 10 x 9 cm in size, occupied the rectum to the margin of the anal sphincter. A surgical procedure was ruled out because of the inability to carry out a safe anastomosis while preserving anal sphincters. Discussion: rectal hemangiomas are less frequent vascular malformations. The clinical presentation of a cavernous hemangioma of the rectum is usually acute, recurrent or chronic rectal bleeding. Other symptoms stem from the possible compression or invasion of adjacent structures, such as lumbar or perianal pain, metrorrhage, hematuria, etc. This diagnosis is commonly made in younger patients. Colonoscopy is without doubt the diagnostic technique of choice, and it allows to establish the localization, morphology, and total extension of the lesion; its characteristic image is a red-purplish nodule with great vascular congestion. According to the opinion of most authors, biopsy is not advisable during colonoscopy, since imaging techniques are sufficient for an accurate diagnosis, and the risk of bleeding while manipulating this lesion is not negligible. Computed tomography and particularly magnetic resonance imaging, given their high precision to delimit the lesion and its relations to adjacent structures, are imaging studies that are mandatory before surgical treatment. Other techniques such as selective angiography, barium enema, gastrointestinal transit, and upper-tract endoscopy may be supplementary and help locate more lesions along the gastrointestinal tract. Failure to recognize the exact diagnosis and extent of diffuse cavernous hemangioma may lead to failed surgical treatment and severe complications. Complete surgical excision of the lesion with a sphincter-saving procedure is the primary mode of treatment: conservative proctectomy with coloanal anastomosis. Objetivo: el hemangioma cavernoso rectal constituye una rara patología, de la cual no se han descrito más de 200 casos en la literatura. El recto y colon sigmoide son la localización más frecuente de esta enfermedad en el tracto gastrointestinal. Caso clínico: a continuación presentamos el caso de un varón de 31 años de edad con episodios recurrentes de sangrado digestivo en forma de rectorragias, el cual finalmente fue dignosticado de hemangioma cavernoso difuso rectal. El tumor, de 12 x 10 x 9 cm de tamaño, ocupaba el recto y se extendía hasta el margen del esfínter anal. El tratamiento quirúrgico fue rechazado ante la imposibilidad de llevar a cabo una resección y una anastomosis segura preservando los esfínteres anales. Discusión: los hemangiomas rectales son malformaciones vasculares infrecuentes que se manifiestan en forma de sangrado rectal agudo, crónico o recurrente como primera sintomatología. Otros síntomas vienen derivados de la compresión de estructuras adyacentes como dolor lumbar o perianal, metrorragias, hematuria, etc. El diagnóstico se realiza casi siempre en adultos jóvenes. La colonoscopia es sin duda la prueba diagnóstica de elección, mostrando la extensión, morfología, características del tumor y la típica imagen es la de una formación nodular, rojo-violácea, con gran congestión vascular. De acuerdo con la opinión de la mayoría de los autores, la toma de biopsias durante la endoscopia no está indicada, dado que las técnicas de imagen son suficientes para el diagnóstico y que el riesgo de sangrado durante la manipulación del tumor no es en absoluto despreciable. La TAC y especiamente la RMN permiten definir mejor la lesión y su relación con estructuras adyacentes, siendo primordiales de cara a un tratamiento quirúrgico. El estudio baritado, la arteriografía selectiva mesentérica o la gastroscopia pueden complementar y descartar además patología similar en otras localizaciones del tracto gastrointestinal. El diagnóstico erróneo de hemangioma cavernoso rectal o de su extensión completa puede derivar en un fallo en el tratamiento quirúrgico y graves complicaciones. La completa resección del tumor preservando los esfínteres anales constituye la técnica quirúrgica de elección: proctectomía conservadora con anastomosis coloanal.
- Published
- 2004
18. P530 Effectiveness of anti-TNF drugs in Crohn's disease (CD) patients who did not achieve remission with the first anti-TNF
- Author
-
R-Grau, M., primary, Chaparro, M., additional, Mesonero, F., additional, Barreiro-de Acosta, M., additional, Castro, L., additional, Vera, I., additional, Castro, M., additional, Domènech, E., additional, Manceñido, N., additional, Taxonera, C., additional, Pérez, J.L., additional, Barrio, J., additional, De Francisco, R., additional, Merino, O., additional, Oltra, L., additional, Saro, C., additional, Bermejo, F., additional, García, V., additional, Ginard, D., additional, Gutiérrez, A., additional, Calvet, X., additional, and Gisbert, J.P., additional
- Published
- 2013
- Full Text
- View/download PDF
19. P216 Inflammatory bowel disease unclassified (IBDU) in real practice: prevalence, clinical course and therapy requirements
- Author
-
Bermejo, F., primary, Algaba, A., additional, Cuño, J.L., additional, Botella, B., additional, Taxonera, C., additional, Calvo, M., additional, López-Serrano, P., additional, Ballesteros, L., additional, Chaparro, M., additional, Ponferrada, A., additional, Manceñido, N., additional, de-la-Poza, G., additional, López-San Román, A., additional, Martin, D., additional, Olivares, D., additional, González-Lama, Y., additional, Pérez-Calle, J.L., additional, Gómez, G., additional, Gisbert, J.P., additional, and Guerra, I., additional
- Published
- 2013
- Full Text
- View/download PDF
20. LA DETERMINACIÓN SISTEMÁTICA DE LOS METABOLITOS DE LA AZATIOPRINA DURANTE EL SEGUIMIENTO DE LOS PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL (EII) TRATADOS CON TIOPURÍNICOS NO ES ÚTIL: RESULTADOS FINALES DEL ESTUDIO METAZA
- Author
-
González-Lama, Y., primary, McNicholl, A.G., additional, Bermejo, F., additional, López-Sanromán, A., additional, García, M.V., additional, Esteve, M., additional, Cabriada, J.L., additional, Pajares, R., additional, Casellas, F., additional, Merino, O., additional, Carpio, D., additional, Calvo, M., additional, Muñoz, C., additional, Benito, L.M., additional, Bufanda, L., additional, García-Hernández, F.J., additional, Ricart, E., additional, Ginard, D., additional, Velasco, M., additional, Carneros, J.A., additional, Manceñido, N., additional, Vera, M.I., additional, Algaba, A., additional, Froilan, C., additional, Abreu, L., additional, Maté, J., additional, Cara, C., additional, and Gisbert, J.P., additional
- Published
- 2009
- Full Text
- View/download PDF
21. P105 ORAL AND INTRAVENOUS (IV) IRON IN THE MANAGEMENT OF IRON DEFICIENCY ANEMIA IN INFLAMMATORY BOWEL DISEASE
- Author
-
Gisbert, J.P., primary, Bermejo, F., additional, Pajares, R., additional, Pérez-Calle, J., additional, Rodríguez, M., additional, Algaba, A., additional, Manceñido, N., additional, de la Morena, F., additional, Carneros, J., additional, McNicholl, A., additional, González-Lama, Y., additional, and Mate, J., additional
- Published
- 2008
- Full Text
- View/download PDF
22. Dynamic evaluation of tumoral transcriptome for a blind study of mechanisms of chemoradiotherapy resistance in rectal cancer patients
- Author
-
Casado, E., primary, Cejas, P., additional, de Castro, J., additional, Vaquez, P., additional, Sanchez, B., additional, Feliu Belda, J., additional, Singh, B., additional, Castelo Ja Fresno, B., additional, Manceñido, N., additional, Perona, R., additional, and Gonzalez Baron, M., additional
- Published
- 2005
- Full Text
- View/download PDF
23. Diffuse cavernous hemangioma of the rectum: an atypical cause of rectal bleeding
- Author
-
Hervías, D., primary, Turrión, J. P., additional, Herrera, M., additional, Navajas León, J., additional, Pajares Villarroya, R., additional, Manceñido, N., additional, Castillo, P., additional, and Segura, J.M., additional
- Published
- 2004
- Full Text
- View/download PDF
24. P614 Incidences and characteristics of intestinal and extraintestinal cancers in patients with inflammatory bowel disease: a population-based study
- Author
-
Algaba, A., Guerra, I., Quintanilla, E., López-Serrano, P., García-Sánchez, M.C., Taxonera, C., Gómez, G.J., Gisbert, J.P., Martín, D., Manceñido, N., Montiel, E., Castaño, A., Pérez-Calle, J.L., Olivares, D., and Bermejo, F.
- Published
- 2014
- Full Text
- View/download PDF
25. Prevalence and antimicrobial-resistance of S. pneumoniae and S. pyogenes in healthy children in the region of Madrid
- Author
-
Herruzo, R, primary, Chamorro, L, additional, Garcı́a, M.E, additional, González, M.C, additional, López, A.M, additional, Manceñido, N, additional, and Yébenes, L, additional
- Published
- 2002
- Full Text
- View/download PDF
26. Manometric findings in adult eosinophilic oesophagitis: a study of 12 cases.
- Author
-
Lucendo AJ, Castillo P, Martín-Chávarri S, Carrión G, Pajares R, Pascual JM, Manceñido N, and Erdozain JC
- Published
- 2007
- Full Text
- View/download PDF
27. P142 - Oral and intravenous iron treatment in inflammatory bowel disease: haematological response and quality of life improvement
- Author
-
Gisbert, J.P., Bermejo, F., Pajares, R., Pérez-Calle, J.L., Rodriguez, M., Algaba, A., Mancenido, N., de la Morena, F., Carneros, J.A., McNicholl, A.G., Gonzalez-Lama, Y., and Maté, J.
- Published
- 2009
- Full Text
- View/download PDF
28. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry.
- Author
-
Casas Deza D, Polo Cuadro C, de Francisco R, Vela González M, Bermejo F, Blanco I, de la Serna Á, Bujanda L, Bernal L, Rueda García JL, Gargallo-Puyuelo CJ, Fuentes-Valenzuela E, Castro B, Guardiola J, Ladrón G, Suria C, Sáez Fuster J, Gisbert JP, Sicilia B, Gomez R, Muñoz Vilafranca C, Barreiro-De Acosta M, Peña E, Castillo Pradillo M, Cerrillo E, Calvet X, Manceñido N, Monfort I Miquel D, Marín S, Roig C, Marce A, Ramírez de Piscina P, Betoré E, Martin-Cardona A, Teller M, Alonso Abreu I, Maroto N, Frago S, Gardeazabal D, Pérez-Martínez I, Febles González ÁD, Barrero S, Taxonera C, García de la Filia I, Ezkurra-Altuna A, Madero L, Martín-Arranz MD, Gomollón F, Domènech E, and García-López S
- Subjects
- Humans, Male, Female, Adult, Spain, Middle Aged, Secondary Prevention methods, Crohn Disease complications, Abdominal Abscess etiology, Abdominal Abscess prevention & control, Abdominal Abscess therapy, Drainage methods, Registries, Anti-Bacterial Agents therapeutic use, Recurrence
- Abstract
Introduction: Intra-abdominal abscesses complicating Crohn's disease [CD] are a challenging situation. Their management, during hospitalisation and after resolution, is still unclear., Methods: Adult patients with CD complicated with intra-abdominal abscess. who required hospitalisation, were included from the prospectively maintained ENEIDA registry from GETECCU. Initial strategy effectiveness and safety to resolve abscess was assessed. Survival analysis was performed to evaluate recurrence risk. Predictive factors associated with resolution were evaluated by multivariate regression and predictive factors associated with recurrence were assessed by Cox regression., Results: In all, 520 patients from 37 Spanish hospitals were included; 322 [63%] were initially treated with antibiotics alone, 128 [26%] with percutaneous drainage, and 54 [17%] with surgical drainage. The size of the abscess was critical to the effectiveness of each treatment. In abscesses < 30 mm, the antibiotic was as effective as percutaneous or surgical drainage. However, in larger abscesses, percutaneous or surgical drainage was superior. In abscesses > 50 mm, surgery was superior to percutaneous drainage, although it was associated with a higher complication rate. After abscess resolution, luminal resection was associated with a lower 1-year abscess recurrence risk [HR 0.43, 95% CI 0.24-0.76]. However, those patients who initiated anti-TNF therapy had a similar recurrence risk whether luminal resection had been performed., Conclusions: Small abscesses [<30mm] can be managed with antibiotics alone; larger ones require drainage. Percutaneous drainage will be effective and safer than surgery in many cases. After discharge, anti-TNF therapy reduces abscess recurrence risk in a similar way to bowel resection., (© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
29. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry.
- Author
-
Guerra I, Barros F, Chaparro M, Benítez JM, Martín-Arranz MD, de Francisco R, Piqueras M, de Castro L, Carbajo AY, Bermejo F, Mínguez M, Gutiérrez A, Mesonero F, Cañete F, González-Muñoza C, Calvo M, Sicilia B, Alfambra E, Rivero M, Lucendo AJ, Tardillo CA, Almela P, Bujanda L, van Domselaar M, Ramos L, Fernández Sánchez M, Hinojosa E, Verdejo C, Gimenez A, Rodríguez-Lago I, Manceñido N, Pérez Calle JL, Moreno MDP, Delgado-Guillena PG, Antolín B, Ramírez de la Piscina P, Casanova MJ, Soto Escribano P, Martín Arranz E, Pérez-Martínez I, Mena R, García Morales N, Granja A, Boscá Watts MM, Francés R, Fernández C, Calafat M, Roig-Ramos C, Vera MI, Carracedo Á, Domènech E, and Gisbert JP
- Subjects
- Humans, Female, Male, Adult, Case-Control Studies, Middle Aged, Genetic Predisposition to Disease, Risk Factors, Genetic Variation, Mercaptopurine adverse effects, Mercaptopurine therapeutic use, Pancreatitis chemically induced, Pancreatitis genetics, Inflammatory Bowel Diseases genetics, Inflammatory Bowel Diseases drug therapy, Registries
- Abstract
Introduction: Risk factors for developing pancreatitis due to thiopurines in patients with inflammatory bowel disease (IBD) are not clearly identified. Our aim was to evaluate the predictive pharmacogenetic risk of pancreatitis in IBD patients treated with thiopurines., Methods: We conducted an observational pharmacogenetic study of acute pancreatitis events in a cohort study of IBD patients treated with thiopurines from the prospectively maintained ENEIDA registry biobank of GETECCU. Samples were obtained and the CASR, CEL, CFTR, CDLN2, CTRC, SPINK1, CPA1, and PRSS1 genes, selected based on their known association with pancreatitis, were fully sequenced., Results: Ninety-five cases and 105 controls were enrolled; a total of 57% were women. Median age at pancreatitis diagnosis was 39 years. We identified 81 benign variants (50 in cases and 67 in controls) and a total of 35 distinct rare pathogenic and unknown significance variants (10 in CEL, 21 in CFTR, 1 in CDLN2, and 3 in CPA1). None of the cases or controls carried pancreatitis-predisposing variants within the CASR, CPA1, PRSS1, and SPINK1 genes, nor a pathogenic CFTR mutation. Four different variants of unknown significance were detected in the CDLN and CPA1 genes; one of them was in the CDLN gene in a single patient with pancreatitis and 3 in the CPA1 gene in 5 controls. After the analysis of the variants detected, no significant differences were observed between cases and controls., Conclusion: In patients with IBD, genes known to cause pancreatitis seem not to be involved in thiopurine-related pancreatitis onset., (© 2024 S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
30. Should Inflammatory Bowel Disease Clinicians Provide Their Patients with e-Health Resources? Patients' and Professionals' Perspectives.
- Author
-
Echarri A, Pérez-Calle JL, Calvo M, Molina G, Sierra-Ausín M, Morete-Pérez MC, Manceñido N, Botella B, Cano N, Castro B, Martín-Rodríguez D, Sánchez-Ortega Y, Corsino P, Cañas M, López-Calleja AM, Nos P, and Muñiz J
- Subjects
- Humans, Surveys and Questionnaires, Internet, Education, Distance, Inflammatory Bowel Diseases therapy
- Abstract
Introduction: n The internet is emerging as a source of information for patients with inflammatory bowel disease (IBD). However, it is not always reliable and may cause anxiety. We aim to assess patients' information habits and patients' and professionals' perceptions of a national website integrated as an educational resource for the IBD unit. n Methods: n Patients aged 18-65 years, comfortable with the internet, and attending follow-ups at participating IBD units (March-June 2019) and their professionals were invited to evaluate a recommended website through an online survey. n Results: n Three hundred eighty-nine patients and 95 professionals completed the survey. The internet ( n = 109; 27.4%) was the second preferred source of information after the health care team ( n = 229; 57.5%). Eighty percent of patients searched the internet for information on their disease and 28.6% did so at least once a week ( n = 114), especially newly diagnosed ones (<2 years). Patients valued a website recommended by their professional ( n = 379; 95.2%) and endorsed by the National Working Group ( n = 377; 94.7%). They would attend online educational initiatives on the website ( n = 279; 70.1%) and complete periodical surveys to improve its usefulness ( n = 338; 84.9%). According to IBD professionals, this type of website is the best patient source of supplementary information ( n = 76; 80%) and they "prescribe" it to most patients (67.0 ± 25.2%), especially the newly diagnosed patients (52.7 ± 26.5%). It effectively integrates routine face-to-face education ( n = 95; 100%). Conclusions: Patients of IBD units, especially newly diagnosed ones, appreciate a trusted e-Health resource to back up professional information. The favorable opinion of patients and professionals will allow its use in training interventions.
- Published
- 2023
- Full Text
- View/download PDF
31. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU.
- Author
-
Barreiro-de Acosta M, Fernández-Clotet A, Mesonero F, García-Alonso FJ, Casanova MJ, Fernández-de la Varga M, Cañete F, de Castro L, Gutiérrez A, Sicilia B, Cano V, Merino O, de Francisco R, González-Partida I, Surís G, Torrealba L, Ferreiro-Iglesias R, Castro B, Márquez L, Sobrino A, Elorza A, Calvet X, Varela P, Vicente R, Bujanda L, Lario L, Manceñido N, García-Sepulcre MF, Iglesias E, Rodríguez C, Piqueras M, Ferrer Rosique JÁ, Lucendo AJ, Benítez O, García M, Olivares D, González-Muñoza C, López-Cauce B, Morales Alvarado VJ, Spicakova K, Brotons A, Bermejo F, Almela P, Ispízua N, Gilabert P, Tardillo C, Muñoz F, Navarro P, Madrigal Domínguez RE, Sendra P, Hinojosa E, Sáinz E, Martín-Arranz MD, Carpio D, Ricart E, Caballol B, Núñez L, Barrio J, Gisbert JP, Iborra M, Calafat M, Hernández V, Muñoz Pérez R, Cabriada JL, Domènech E, and Rodríguez-Lago I
- Subjects
- Adult, Humans, Ustekinumab therapeutic use, Treatment Outcome, Biological Therapy, Necrosis, Retrospective Studies, Crohn Disease complications, Crohn Disease drug therapy, Crohn Disease surgery, Fistula, Rectal Fistula etiology, Rectal Fistula therapy
- Abstract
Introduction: The prevalence of penetrating complications in Crohn's disease (CD) increases progressively over time, but evidence on the medical treatment in this setting is limited. The aim of this study was to evaluate the effectiveness of biologic agents in CD complicated with internal fistulizing disease., Methods: Adult patients with CD-related fistulae who received at least 1 biologic agent for this condition from the prospectively maintained ENEIDA registry were included. Exclusion criteria involved those receiving biologics for perianal disease, enterocutaneous, rectovaginal, anastomotic, or peristomal fistulae. The primary end point was fistula-related surgery. Predictive factors associated with surgery and fistula closure were evaluated by multivariate logistic regression and survival analyses., Results: A total of 760 patients from 53 hospitals (673 receiving anti-tumor necrosis factors, 69 ustekinumab, and 18 vedolizumab) were included. After a median follow-up of 56 months (interquartile range, 26-102 months), 240 patients required surgery, with surgery rates of 32%, 41%, and 24% among those under anti-tumor necrosis factor, vedolizumab, or ustekinumab, respectively. Fistula closure was observed in 24% of patients. Older patients, ileocolonic disease, entero-urinary fistulae, or an intestinal stricture distal to the origin of the fistula were associated with a higher risk of surgery, whereas nonsmokers and combination therapy with an immunomodulator reduced this risk., Discussion: Biologic therapy is beneficial in approximately three-quarters of patients with fistulizing CD, achieving fistula closure in 24%. However, around one-third still undergo surgery due to refractory disease. Some patient- and lesion-related factors can identify patients who will obtain more benefit from these drugs., (Copyright © 2023 by The American College of Gastroenterology.)
- Published
- 2023
- Full Text
- View/download PDF
32. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.
- Author
-
Casas-Deza D, Lamuela-Calvo LJ, Gomollón F, Arbonés-Mainar JM, Caballol B, Gisbert JP, Rivero M, Sánchez-Rodríguez E, Arias García L, Gutiérrez Casbas A, Merino O, Márquez L, Laredo V, Martín-Arranz MD, López Serrano P, Riestra Menéndez S, González-Muñoza C, de Castro Parga L, Calvo Moya M, Fuentes-Valenzuela E, Esteve M, Iborra M, Dura Gil M, Barreiro-De Acosta M, Lorente-Poyatos RH, Manceñido N, Calafat M, Rodríguez-Lago I, Guardiola Capo J, Payeras MA, Morales Alvarado VJ, Tardillo C, Bujanda L, Muñoz-Nuñez JF, Ber Nieto Y, Bermejo F, Almela P, Navarro-Llavat M, Martínez Montiel P, Rodríguez Gutiérrez C, Van Domselaar M, Sesé E, Martínez Pérez T, Ricart E, Chaparro M, García MJ, López-Sanromán A, Sicilia B, Orts B, López-García A, Martín-Arranz E, Pérez-Calle JL, de Francisco R, García-Planella E, Domènech E, and García-López YS
- Subjects
- Humans, Middle Aged, Aged, Remission Induction, Endoscopy, Registries, Treatment Outcome, Retrospective Studies, Ustekinumab adverse effects, Crohn Disease pathology
- Abstract
Background and Aims: Clinical trials and real-life studies with ustekinumab in Crohn's disease [CD] have revealed a good efficacy and safety profile. However, these data are scarcely available in elderly patients. Therefore, we aim to assess the effectiveness and safety of ustekinumab in elderly patients with CD., Methods: Elderly patients [>60 years old] from the prospectively maintained ENEIDA registry treated with ustekinumab due to CD were included. Every patient was matched with two controls under 60 years of age, according to anti-tumour necrosis factor use and smoking habit. Values for the Harvey-Bradshaw Index [HBI], endoscopic activity, C-reactive protein [CRP] and faecal calprotectin [FC] were recorded at baseline and at weeks 16, 32 and 54., Results: In total, 648 patients were included, 212 of whom were elderly. Effectiveness was similar between young and elderly patients during the follow-up. Steroid-free remission was similar at week 16 [54.6 vs 51.4%, p = 0.20], 32 [53.0% vs 54.5%, p = 0.26] and 54 [57.8% vs 51.1%, p = 0.21]. Persistence of ustekinumab as maintenance therapy was similar in both age groups [log-rank test; p = 0.91]. There was no difference in the rate of adverse effects [14.2% vs 11.2%, p = 0.350], including severe infections [7.1% vs 7.3%, p = 1.00], except for the occurrence of de novo neoplasms, which was higher in older patients [0.7% vs 4.3%, p = 0.003]., Conclusions: Ustekinumab is as effective in elderly patients with CD as it is in non-elderly patients. The safety profile also seems to be similar except for a higher rate of de novo neoplasms, probably related to the age of the elderly patients., (© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
33. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry.
- Author
-
Mañosa M, Fernández-Clotet A, Nos P, Martín-Arranz MD, Manceñido N, Carbajo A, Hinojosa E, Hernández-Camba A, Muñoz-Pérez R, Boscá-Watts M, Calvo M, Sierra-Ausín M, Sánchez-Rodríguez E, Barreiro-de Acosta M, Núñez-Alonso A, Zabana Y, Márquez L, Gisbert JP, Guardiola J, Sáinz E, Delgado-Guillena P, Busquets D, van Domselaar M, Girona E, Lorente R, Casas-Deza D, Huguet JM, Maestro S, Cabello MJ, Castro J, Iborra M, Cañete F, Calafat M, and Domènech E
- Subjects
- Humans, Tumor Necrosis Factor Inhibitors therapeutic use, Registries, Retrospective Studies, Treatment Outcome, Ustekinumab therapeutic use, Crohn Disease drug therapy, Crohn Disease prevention & control, Crohn Disease surgery
- Abstract
Background: Anti-TNF agents are the only effective biological agents for the prevention of postoperative recurrence (POR) in Crohn's disease (CD). However, they are contraindicated or have been shown to fail in some patients. Although ustekinumab and vedolizumab were licensed for CD some years ago, data in this setting are scarce., Methods: All CD patients in whom ustekinumab or vedolizumab was prescribed for the prevention of POR within three months of ileocolonic resection with anastomosis were identified from the ENEIDA registry. The development of endoscopic, clinical and surgical POR was registered., Results: Forty patients were treated for the prevention of POR with ustekinumab and 25 were treated with vedolizumab. Eighty per cent had at least one risk factor for POR (prior resections, active smoking, perianal disease or penetrating disease behaviour). All the patients had been exposed to anti-TNF therapy. After a median follow-up of 17 and 26 months, the cumulative probability of clinical POR at 12 months after surgery was 32% and 30% for ustekinumab and vedolizumab, respectively. Endoscopic assessment within the first 18 months after surgery was available for 80% of the patients on ustekinumab and 70% for those on vedolizumab. The rate of endoscopic POR was 42% for ustekinumab and 40% for vedolizumab. One patient treated with ustekinumab and two with vedolizumab underwent a new intestinal resection., Conclusions: Ustekinumab and vedolizumab seem to be effective in the prevention of POR in patients at high risk. Our results warrant controlled trials comparing these drugs with conventional therapies., Competing Interests: Declaration of Competing Interest MM has served as a speaker, consultant and advisory member for or has received research funding from AbbVie, Gilead, Janssen, MSD, Pfizer, Shire Pharmaceuticals, Faes, Takeda, Tillots; PN has served as a speaker, consultant and advisory member for or has received research funding from MSD, Abbvie, Janssen, Takeda, Roche, Sandoz, Ferring, Adacyte, Faes Farma, Kern Pharma, Pfizer, Shire Pharmaceuticals, Vifor Pharma, Chiesi and Tillots; MDM-A has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Hospira, Pfizer, Takeda, Janssen, Shire Pharmaceuticals, Tillotts Pharma, FaesPharma; MB-W has served as a speaker, consultant and advisory member for or has received research funding from MSD, Ferring, Abbvie, Janssen, Biogen and Takeda; MC has served as a speaker, consultant and advisory member for or has received research funding from MSD, Abbvie, Takeda, Jannsen, Pfizer, Otsuka Pharmaceutical, Chiesi, Ferring, Shire Pharmaceuticals and Dr. Falk Pharma; MS-A has served as a speaker, consultant and advisory member for or has received research funding from Takeda, Janssen, MSD, Abbvie, Ferring, Chiesi, Tillots and Pfizer; MBA has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Gillead, Celgene, Pfizer, Sandoz, Biogen, Fresenius, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Gebro Pharma, Adacyte and Vifor Pharma; YZ has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Takeda, Kern Pharma, Biogen; JPG has served as a speaker, consultant and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene, Gilead, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma; JG has served as a speaker, consultant and advisory member for or has received research funding from Roche, MSD, Abbvie, Kern Pharma, Takeda, Janssen, Pfizer, Ferring, Chiesi and GE Healthcare; DB has served as a speaker, consultant and advisory member for or has received research funding from Abbvie, Janssen, Ferring, Pfizer, and Takeda; DC-D has served as a speaker, consultant and advisory member for or has received research funding from MSD, Ferring, Abbvie, Janssen, Faes Farma, Pfizer, Tillots and Takeda; SM has served as a speaker, consultant and advisory member for or has received research funding from MSD, Ferring, Abbvie, Janssen, Pfizer and Takeda; LM has served as a speaker and advisory member for or has received research funding from MSD, Takeda, Janssen, Abbvie and Pfizer; FC has served as a speaker, consultant and advisory member for or has received research funding from Takeda, Janssen, MSD, and Ferring; MC has served as a speaker, consultant and advisory member for or has received research funding from Takeda, Janssen, Faes Farma, and MSD; ED has served as a speaker, consultant and advisory member for or has received research funding from AbbVie, Adacyte Therapeutics, Celltrion, Gilead, Janssen, Kern Pharma, MSD, Pfizer, Roche, Samsung, Takeda, Tillots, Ferring, and Thermofisher; the remaining authors have no potential conflicts to declare., (Copyright © 2022. Published by Elsevier Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
34. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII).
- Author
-
Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I, P Gisbert J, Mesonero F, Benítez O, Taxonera C, Ponferrada-Díaz Á, Piqueras M, J Lucendo A, Caballol B, Mañosa M, Martínez-Montiel P, Bosca-Watts M, Gordillo J, Bujanda L, Manceñido N, Martínez-Pérez T, López A, Rodríguez-Gutiérrez C, García-López S, Vega P, Rivero M, Melcarne L, Calvo M, Iborra M, Barreiro de Acosta M, Sicilia B, Barrio J, Pérez Calle JL, Busquets D, Pérez-Martínez I, Navarro-Llavat M, Hernández V, Argüelles-Arias F, Ramírez Esteso F, Meijide S, Ramos L, Gomollón F, Muñoz F, Suris G, Ortiz de Zarate J, Huguet JM, Llaó J, García-Sepulcre MF, Sierra M, Durà M, Estrecha S, Fuentes Coronel A, Hinojosa E, Olivan L, Iglesias E, Gutiérrez A, Varela P, Rull N, Gilabert P, Hernández-Camba A, Brotons A, Ginard D, Sesé E, Carpio D, Aceituno M, Cabriada JL, González-Lama Y, Jiménez L, Chaparro M, López-San Román A, Alba C, Plaza-Santos R, Mena R, Tamarit-Sebastián S, Ricart E, Calafat M, Olivares S, Navarro P, Bertoletti F, Alonso-Galán H, Pajares R, Olcina P, Manzano P, Domènech E, Esteve M, and On Behalf Of The Eneida Registry Of Geteccu
- Abstract
(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case−control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March−July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3−5.9), occupational risk (OR: 2.9; 95%CI: 1.8−4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2−2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09−0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution.
- Published
- 2022
- Full Text
- View/download PDF
35. Polyphenols and Ulcerative Colitis: An Exploratory Study of the Effects of Red Wine Consumption on Gut and Oral Microbiome in Active-Phase Patients.
- Author
-
Taladrid D, Zorraquín-Peña I, Molinero N, Silva M, Manceñido N, Pajares R, Bartolomé B, and Moreno-Arribas MV
- Subjects
- Humans, Polyphenols analysis, RNA, Ribosomal, 16S genetics, RNA, Ribosomal, 16S analysis, Feces microbiology, Colitis, Ulcerative microbiology, Wine analysis, Microbiota
- Abstract
Scope: This paper explores the effects of moderate red wine consumption on the clinical status and symptomatology of patients with ulcerative colitis (UC), including the study of the oral and intestinal microbiome., Methods and Results: A case control intervention study in UC patients is designed. Intervention patients (n = 5) consume red wine (250 mL day
-1 ) for 4 weeks whereas control patients (n = 5) do not. Moderate wine consumption significantly (p < 0.05) improves some clinical parameters related to serum iron, and alleviates intestinal symptoms as evaluated by the IBDQ-32 questionnaire. 16S rRNA gene sequencing indicate a non-significant (p > 0.05) increase in bacterial alpha diversity after wine intervention in both saliva and fecal microbiota. Additional comparison of taxonomic data between UC patients (n = 10) and healthy subjects (n = 8) confirm intestinal dysbiosis for the UC patients. Finally, analysis of fecal metabolites (i.e., phenolic acids and SCFAs) indicates a non-significant increase (p > 0.05) for the UC patients that consumed wine., Conclusions: Moderate and regular red wine intake seems to improve the clinical status and symptoms of UC patients in the active phase of the disease. However, studies with a greater sample size are required to achieve conclusive results., (© 2022 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH GmbH.)- Published
- 2022
- Full Text
- View/download PDF
36. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs-Findings From the BIOCOVID Study.
- Author
-
Muñoz-Fernández S, Cebrian L, Thuissard IJ, Steiner M, García-Yubero C, Esteban AV, Sánchez F, Gómez A, Matías MA, Cobo-Ibáñez T, Esteban M, Manceñido N, Pajares R, Arribas MR, Martínez A, Andreu C, Esteban C, Romero L, and Navío T
- Subjects
- Cross-Sectional Studies, Humans, Incidence, SARS-CoV-2, Antirheumatic Agents therapeutic use, Biosimilar Pharmaceuticals, COVID-19
- Abstract
Objectives: The aim of this study was to examine the incidence of coronavirus disease 2019 (COVID-19) among patients with immunomediated inflammatory diseases (IMIDs) treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) and to evaluate the influence of either IMIDs or related therapies on the incidence and evolution of COVID-19., Methods: This observational, cross-sectional study was conducted from January 31, 2020, to May 15, 2020. Data of 902 patients were obtained from clinical records in hospitals, primary care units, and community pharmacies. Inclusion criteria were adults with IMIDs treated with bDMARDs or tsDMARDs who started therapy 3 months prior to study commencement. Patients with poor adherence to treatments were excluded. COVID-19 was classified as "definitive" (severe acute respiratory syndrome coronavirus 2 polymerase chain reaction [PCR]-positive), "possible" (characteristic symptoms and negative PCR), and "suspected" (characteristic symptoms but PCR not performed)., Results: COVID-19 was diagnosed in 70 patients (11 definitive, 19 possible, and 40 suspected). The cumulative incidence of definitive COVID-19 was 1.2%. When considering all cases, the incidence was 7.8%. Patients on biosimilars tumor necrosis factor blockers were more likely to have a diagnosis of COVID-19 (odds ratio, 2.308; p < 0.001). Patients on anti-B-cell therapies had a lower incidence of infections (p = 0.046). Low rates of hospitalization (14.3%), pneumonia (14.3%), death (2.9%), or thrombosis (2.9%) were observed, and 94.3% of patients recovered., Conclusions: The cumulative incidence of confirmed cases of COVID-19 was similar to the general population, with generally low hospitalization, intensive care management, and mortality rates. COVID-19 incidence was less frequent in patients with more severe immunosuppression., Competing Interests: The authors declare no conflict of interest., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
37. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients.
- Author
-
Gutiérrez A, Zapater P, Ricart E, González-Vivó M, Gordillo J, Olivares D, Vera I, Mañosa M, Gisbert JP, Aguas M, Sánchez-Rodríguez E, Bosca-Watts M, Laredo V, Camps B, Marín-Jiménez I, Zabana Y, Martín-Arranz MD, Muñoz R, Navarro M, Sierra E, Madero L, Vela M, Pérez-Calle JL, Sainz E, Calvet X, Arias L, Morales V, Bermejo F, Fernández-Salazar L, Van Domselaar M, De Castro L, Rodríguez C, Muñoz-Villafranca C, Lorente R, Rivero M, Iglesias E, Herreros B, Busquets D, Riera J, Martínez-Montiel MP, Roldón M, Roncero O, Hinojosa E, Sierra M, Barrio J, De Francisco R, Huguet J, Merino O, Carpio D, Ginard D, Muñoz F, Piqueras M, Almela P, Argüelles-Arias F, Alcaín G, Bujanda L, Manceñido N, Lucendo AJ, Varela P, Rodríguez-Lago I, Ramos L, Sempere L, Sesé E, Barreiro-de Acosta M, Domènech E, and Francés R
- Abstract
Background: Previous studies comparing immigrant ethnic groups and native patients with IBD have yielded clinical and phenotypic differences. To date, no study has focused on the immigrant IBD population in Spain., Methods: Prospective, observational, multicenter study comparing cohorts of IBD patients from ENEIDA-registry who were born outside Spain with a cohort of native patients., Results: We included 13,524 patients (1,864 immigrant and 11,660 native). The immigrants were younger (45 ± 12 vs. 54 ± 16 years, p < 0.001), had been diagnosed younger (31 ± 12 vs. 36 ± 15 years, p < 0.001), and had a shorter disease duration (14 ± 7 vs. 18 ± 8 years, p < 0.001) than native patients. Family history of IBD (9 vs. 14%, p < 0.001) and smoking (30 vs. 40%, p < 0.001) were more frequent among native patients. The most prevalent ethnic groups among immigrants were Caucasian (41.5%), followed by Latin American (30.8%), Arab (18.3%), and Asian (6.7%). Extraintestinal manifestations, mainly musculoskeletal affections, were more frequent in immigrants (19 vs. 11%, p < 0.001). Use of biologics, mainly anti-TNF, was greater in immigrants (36 vs. 29%, p < 0.001). The risk of having extraintestinal manifestations [OR: 2.23 (1.92-2.58, p < 0.001)] and using biologics [OR: 1.13 (1.0-1.26, p = 0.042)] was independently associated with immigrant status in the multivariate analyses., Conclusions: Compared with native-born patients, first-generation-immigrant IBD patients in Spain were younger at disease onset and showed an increased risk of having extraintestinal manifestations and using biologics. Our study suggests a featured phenotype of immigrant IBD patients in Spain, and constitutes a new landmark in the epidemiological characterization of immigrant IBD populations in Southern Europe., Competing Interests: AG has served as speaker, consultant and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Tillotts Pharma, Chiesi and Otsuka Pharmaceutical. ER has provided scientific advice/participated in medical meetings/received research funding from/received payment for presentations and advice from: MSD, Schering-Plow, Ferring, Abbvie, Takeda, Janssen, Fresenius Kabi, Pfizer. IV has served as a speaker, or has received research or education funding from Abbvie, MSD, Pfizer, Takeda, Janssen, Tillotts Pharma, Ferring and Shire Pharmaceuticals. MM has served as speaker or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Biogen, Tillotts Pharma, Chiesi and Adacyte. JPG has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene, Gilead/Galapagos, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma. YZ has received support for conference attendance, speaker fees, research support and consulting fees from Abbvie, Adacyte, Almirall, Amgen, Dr. Falk, FAES Pharma, Ferring, Janssen, MSD, Otsuka, Pfizer, Shire, Takeda and Tillots. XC has received grants for research from Abbvie, MSD, Vifor fees for advisory boards form Abbvie, MSD, Takeda, Pfizer, Janssen and VIFOR and has given lectures for Abbvie, MSD, Janssen, Pfizer, Takeda, Shire and Allergan. FB has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Takeda, Janssen, Pfizer, Biogen, Amgen, Ferring, Faes Farma, Tillotts Pharma, Falk Pharma, Chiesi, Gebro Pharma, Vifor Pharma. MM-M has served as speaker, consultant and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Takeda, Janssen, Shire Pharmaceuticals and Otsuka Pharmaceutical. MR has served as speaker, consultant or advisory member for MSD, Abbvie, Pfizer, Takeda, Janssen, Ferring and Chiesi. MP has served as speaker or has received research funding from Abbvie, Takeda and Janssen. IR-L has received financial support for traveling and educational activities from or has served as an advisory board member for MSD, Pfizer, Abbvie, Takeda, Janssen, Tillotts Pharma, Shire Pharmaceuticals, Roche, Celltrion, Faes Farma, Ferring, Dr. Falk Pharma, Otsuka Pharmaceutical and Adacyte. Financial support for research from Tillotts Pharma. RL has served as a speaker, or has received research or education funding from MSD, Abbvie, Pfizer, Takeda, Janssen and Dr. Falk. LA has served as speaker, or has received research or education funding from MSD, Abbvie, Kern Pharma, Ferring, FaesFarma, Shire Pharmaceuticals, Pfizer, Takeda, Janssen, Tillotts Pharma, and Otsuka Pharmaceutical. FA-A has served as speaker, consultant and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Tillotts Pharma, Chiesi and Dr. Falk. LR has served as a speaker, or has received education funding from MSD, Abbvie, Adacyte, Takeda, Pfizer, Janssen and Ferring. MB-d has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Gillead, Celgene, Pfizer, Sandoz, Biogen, Fresenius, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Gebro Pharma, Adacyte and Vifor Pharma. ED has served as a speaker, or has received research or education funding or advisory fees from AbbVie, Adacyte Therapeutics, Biogen, Celltrion, Gilead, Janssen, Kern Pharma, MSD, Pfizer, Roche, Samsung, Takeda, Tillots, Thermofisher. RF has served as a speaker, or has received research or education funding or advisory fees from AbbVie, Janssen, Takeda, Adacyte Therapeutics, Sanofi, GlaxoSmithKline, Almirall. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Gutiérrez, Zapater, Ricart, González-Vivó, Gordillo, Olivares, Vera, Mañosa, Gisbert, Aguas, Sánchez-Rodríguez, Bosca-Watts, Laredo, Camps, Marín-Jiménez, Zabana, Martín-Arranz, Muñoz, Navarro, Sierra, Madero, Vela, Pérez-Calle, Sainz, Calvet, Arias, Morales, Bermejo, Fernández-Salazar, Van Domselaar, De Castro, Rodríguez, Muñoz-Villafranca, Lorente, Rivero, Iglesias, Herreros, Busquets, Riera, Martínez-Montiel, Roldón, Roncero, Hinojosa, Sierra, Barrio, De Francisco, Huguet, Merino, Carpio, Ginard, Muñoz, Piqueras, Almela, Argüelles-Arias, Alcaín, Bujanda, Manceñido, Lucendo, Varela, Rodríguez-Lago, Ramos, Sempere, Sesé, Barreiro-de Acosta, Domènech and Francés.)
- Published
- 2022
- Full Text
- View/download PDF
38. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry.
- Author
-
Chaparro M, Garre A, Iborra M, Sierra-Ausín M, Barreiro-de Acosta M, Fernández-Clotet A, de Castro L, Boscá-Watts M, Casanova MJ, López-García A, Lorente R, Rodríguez C, Carbajo AY, Arroyo MT, Gutiérrez A, Hinojosa J, Martínez-Pérez T, Villoria A, Bermejo F, Busquets D, Camps B, Cañete F, Manceñido N, Monfort D, Navarro-Llavat M, Pérez-Calle JL, Ramos L, Rivero M, Angueira T, Camo Monterde P, Carpio D, García-de-la-Filia I, González-Muñoza C, Hernández L, Huguet JM, Morales VJ, Sicilia B, Vega P, Vera I, Zabana Y, Nos P, Suárez Álvarez P, Calviño-Suárez C, Ricart E, Hernández V, Mínguez M, Márquez L, Hervías Cruz D, Rubio Iturria S, Barrio J, Gargallo-Puyuelo C, Francés R, Hinojosa E, Del Moral M, Calvet X, Algaba A, Aldeguer X, Guardiola J, Mañosa M, Pajares R, Piqueras M, García-Bosch O, López Serrano P, Castro B, Lucendo AJ, Montoro M, Castro Ortiz E, Mesonero F, García-Planella E, Fuentes DA, Bort I, Delgado-Guillena P, Arias L, Iglesias A, Calvo M, Esteve M, Domènech E, and Gisbert JP
- Subjects
- Female, Humans, Infusions, Intravenous, Male, Middle Aged, Prospective Studies, Registries, Remission Induction, Ustekinumab administration & dosage, Colitis, Ulcerative drug therapy, Ustekinumab therapeutic use
- Abstract
Background and Aims: The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life., Methods: Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at Week 16., Results: A total of 95 patients were included. At Week 16, 53% of patients had response [including 35% of patients in remission]. In the multivariate analysis, elevated serum C-reactive protein was the only variable significantly associated with lower likelihood of achieving remission. Remission was achieved in 39% and 33% of patients at Weeks 24 and 52, respectively; 36% of patients discontinued the treatment with ustekinumab during a median follow-up of 31 weeks. The probability of maintaining ustekinumab treatment was 87% at Week 16, 63% at Week 56, and 59% at Week 72; primary failure was the main reason for ustekinumab discontinuation. No variable was associated with risk of discontinuation. Three patients reported adverse events; one of them had a fatal severe SARS-CoV-2 infection., Conclusions: Ustekinumab is effective in both the short and the long term in real life, even in a highly refractory cohort. Higher inflammatory burden at baseline correlated with lower probability of achieving remission. Safety was consistent with the known profile of ustekinumab., (© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
39. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
- Author
-
Chaparro M, Garre A, Mesonero F, Rodríguez C, Barreiro-de Acosta M, Martínez-Cadilla J, Arroyo MT, Manceñido N, Sierra-Ausín M, Vera-Mendoza I, Casanova MJ, Nos P, González-Muñoza C, Martínez T, Boscá-Watts M, Calafat M, Busquets D, Girona E, Llaó J, Martín-Arranz MD, Piqueras M, Ramos L, Surís G, Bermejo F, Carbajo AY, Casas-Deza D, Fernández-Clotet A, García MJ, Ginard D, Gutiérrez-Casbas A, Hernández L, Lucendo AJ, Márquez L, Merino-Ochoa O, Rancel FJ, Taxonera C, López Sanromán A, Rubio S, Domènech E, and Gisbert JP
- Subjects
- Dose-Response Relationship, Drug, Drug Monitoring methods, Female, Humans, Male, Middle Aged, Patient Acuity, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Recurrence, Registries statistics & numerical data, Spain epidemiology, Treatment Outcome, Colitis, Ulcerative diagnosis, Colitis, Ulcerative drug therapy, Colitis, Ulcerative epidemiology, Piperidines administration & dosage, Piperidines adverse effects, Pyrimidines administration & dosage, Pyrimidines adverse effects, Remission Induction methods
- Abstract
Aim: To evaluate the effectiveness and safety of tofacitinib in ulcerative colitis [UC] in real life., Methods: Patients from the prospectively maintained ENEIDA registry and treated with tofacitinib due to active UC were included. Clinical activity and effectiveness were defined based on Partial Mayo Score [PMS]. Short-term response/remission was assessed at Weeks 4, 8, and 16., Results: A total of 113 patients were included. They were exposed to tofacitinib for a median time of 44 weeks. Response and remission at Week 8 were 60% and 31%, respectively. In multivariate analysis, higher PMS at Week 4 (odds ratio [OR] = 0].2; 95% confidence interval [CI] = 0].1-0.4) was the only variable associated with lower likelihood of achieving remission at Week 8. Higher PMS at Week 4 [OR = 0.5; 95% CI = 0.3-0.7] and higher PMS at Week 8 [OR = 0.2; 95% CI = 0.1-0.5] were associated with lower probability of achieving remission at Week 16. A total of 45 patients [40%] discontinued tofacitinib over time. Higher PMS at Week 8 was the only factor associated with higher tofacitinib discontinuation [hazard ratio = 1.5; 95% CI = 1.3-1.6]. A total of 34 patients had remission at Week 8; of these, 65% had relapsed 52 weeks after achieving remission; the dose was increased to 10 mg/12 h in nine patients, and five of them reached remission again. Seventeen patients had adverse events., Conclusions: Tofacitinib is effective and safe in UC patients in real practice, even in a highly refractory cohort. A relevant proportion of patients discontinue the drug over time, mainly due to primary failure., (© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
40. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis.
- Author
-
Taxonera C, Iborra M, Bosca-Watts MM, Rubio S, Nantes Ó, Higuera R, Bertoletti F, Martínez-Montiel P, Sierra-Ausin M, Manceñido N, Lázaro Pérez-Calle J, Algaba A, Olivares D, and Alba C
- Subjects
- Adrenal Cortex Hormones therapeutic use, Adult, Aged, Cohort Studies, Female, Humans, Male, Middle Aged, Remission Induction, Severity of Illness Index, Treatment Outcome, Young Adult, Antibodies, Monoclonal administration & dosage, Colitis, Ulcerative drug therapy
- Abstract
Aim: To evaluate outcomes of early dose optimization of golimumab in ulcerative colitis (UC) patients with inadequate response to golimumab induction treatment. Methods: This observational, multicenter, cohort study included patients with moderate-to-severe active UC and with inadequate response to subcutaneous golimumab induction doses, in whom weight-based golimumab maintenance dose (European labeling) of 50 mg every 4 weeks (q4wk) was optimized before week 14 to 100 mg q4wk. At week 14, we assessed clinical response and remission using the partial Mayo score. In the long term we evaluate the cumulative probabilities of golimumab failure-free survival and colectomy-free survival. Results: A total of 209 patients who received golimumab induction doses were eligible. Of these, 151 patients (72.2%) weighing less than 80 kg were assigned to a golimumab maintenance dose of 50 mg q4wk. Twenty-four patients (15.9% [12.5% overall]), in whom scheduled doses of 50 mg q4wk were optimized to 100 mg q4wk before week 14, compose the study population. At week 14, 16 patients (66.7%, 95% CI 45.7-87.6) had clinical response, of these 12 were corticosteroid free. Four patients (16.7%) achieved corticosteroid-free remission. After a median follow-up of 12 months (IQR 10-22), 13 patients (54.2%) maintained clinical benefit. Thirteen of 16 patients (81.2%) with clinical response at week 14 maintained clinical benefit at last follow-up. All patients avoided colectomy. In none of the patients was golimumab dose de-escalated. There were no adverse events leading to golimumab withdrawal. Conclusion: Early optimization of golimumab dose induces clinical response at week 14 in two thirds of UC patients and leads to long-term clinical benefit in over half of patients.
- Published
- 2019
- Full Text
- View/download PDF
41. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients.
- Author
-
Barreiro-de Acosta M, Marín-Jiménez I, Panadero A, Guardiola J, Cañas M, Gobbo Montoya M, Modino Y, Alcaín G, Bosca-Watts MM, Calvet X, Casellas F, Chaparro M, Fernández Salazar L, Ferreiro-Iglesias R, Ginard D, Iborra M, Manceñido N, Mañosa M, Merino O, Rivero M, Roncero O, Sempere L, Vega P, Zabana Y, Mínguez M, Nos P, and Gisbert JP
- Subjects
- Affective Symptoms diagnosis, Affective Symptoms drug therapy, Affective Symptoms etiology, Anti-Anxiety Agents therapeutic use, Antidepressive Agents therapeutic use, Anxiety Disorders diagnosis, Anxiety Disorders etiology, Depressive Disorder diagnosis, Depressive Disorder etiology, Disease Management, Emotions, Humans, Quality of Life, Risk Factors, Sexual Dysfunctions, Psychological etiology, Anxiety Disorders drug therapy, Depressive Disorder drug therapy, Inflammatory Bowel Diseases psychology
- Abstract
Aims: To establish recommendations for the management of psychological problems affecting patients with inflammatory bowel disease (IBD)., Methods: A meeting of a group of IBD experts made up of doctors, psychologists, nurses and patient representatives was held. The following were presented: 1) Results of a previous focal group, 2) Results of doctor and patient surveys, 3) Results of a systematic review of tools for detecting anxiety and depression. A guided discussion was then held about the most important psychological and emotional problems associated with IBD, appropriate referral criteria and situations to be avoided. The validated instrument most applicable to clinical practice was selected. A recommendations document and a Delphi survey were designed. The survey was sent to the group and to a scientific committee of the GETECCU group in order to establish the level of agreement with these recommendations., Results: Fifteen recommendations were established linked to 3 key processes: 1) What steps should be taken to identify psychological problems at an IBD appointment; 2) What are the criteria for referring patients to a mental health specialist; 3) How to approach psychological problems., Conclusions: Resources should be made available to healthcare professionals so that they can treat these problems during consultations, identify the disorders which could affect the clinical course of the disease and determine their impact on the patient's life in order that these can be treated and followed up by the most suitable professional. These recommendations could serve as a basis for redesigning IBD services or processes and as justification for the training of healthcare personnel., (Copyright © 2017 Elsevier España, S.L.U. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
42. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.
- Author
-
Taxonera C, Rodríguez C, Bertoletti F, Menchén L, Arribas J, Sierra M, Arias L, Martínez-Montiel P, Juan A, Iglesias E, Algaba A, Manceñido N, Rivero M, Barreiro-de Acosta M, López-Serrano P, Argüelles-Arias F, Gutierrez A, Busquets D, Gisbert JP, Olivares D, Calvo M, and Alba C
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Colitis, Ulcerative pathology, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Remission Induction, Retrospective Studies, Survival Rate, Young Adult, Antibodies, Monoclonal therapeutic use, Colitis, Ulcerative drug therapy, Colitis, Ulcerative mortality, Severity of Illness Index, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Background: Golimumab efficacy data in ulcerative colitis (UC) are limited to anti-tumor necrosis factor α (TNF)-naive patients. The aim of this study was to assess the short-term and long-term efficacy of golimumab used as first, second, or third anti-TNF in UC in a real-life clinical setting., Methods: This retrospective multicenter cohort study included patients with moderate-to-severe UC treated with golimumab. The primary efficacy endpoints were short-term partial Mayo score response, long-term golimumab failure-free survival, and colectomy-free survival., Results: In 142 patients with UC, golimumab was administered as first (40%), second (23%), or third anti-TNF (37%). Ninety-two patients (65%, 95% confidence interval 56.6-73) achieved short-term clinical response. Forty-five patients (32%, 95% confidence interval 23.7-39.7) achieved clinical remission. Response rates for golimumab were 75% as first anti-TNF, 70% as second anti-TNF (ns versus first anti-TNF), and 50% as third anti-TNF (P = 0.007 versus first anti-TNF). After 12 months median follow-up (interquartile range 6-18), 60 patients (42%, 95% confidence interval 34-51) had golimumab failure, and 15 patients (11%) needed colectomy. Thirty-one patients (22%) needed golimumab dose escalation, and 71% of these regained response after escalation. Starting maintenance with 100 mg golimumab doses and short-term nonresponse were independent predictors of golimumab failure., Conclusions: In this real-life cohort of patients with UC, golimumab therapy was effective for inducing and maintaining clinical response. Although anti-TNF-naive patients had better outcomes, golimumab was also effective in anti-TNF-experienced patients. Only the patients given golimumab after previous failure of 2 anti-TNF agents had significantly worse outcomes. Golimumab dose escalation was beneficial and safe.
- Published
- 2017
- Full Text
- View/download PDF
43. Incidence, management, and course of cancer in patients with inflammatory bowel disease.
- Author
-
Algaba A, Guerra I, Marín-Jiménez I, Quintanilla E, López-Serrano P, García-Sánchez MC, Casis B, Taxonera C, Moral I, Chaparro M, Martín-Rodríguez D, Martín-Arranz MD, Manceñido N, Menchén L, López-Sanromán A, Castaño Á, and Bermejo F
- Subjects
- Female, Follow-Up Studies, Humans, Incidence, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases epidemiology, Male, Middle Aged, Neoplasms etiology, Neoplasms prevention & control, Retrospective Studies, Risk Factors, Spain epidemiology, Time Factors, Anti-Inflammatory Agents therapeutic use, Disease Management, Immunosuppressive Agents therapeutic use, Inflammatory Bowel Diseases complications, Neoplasms epidemiology, Risk Assessment methods
- Abstract
Background and Aims: Patients with inflammatory bowel disease [IBD] are at increased risk for developing some types of neoplasia. Our aims were to determin the risk for cancer in patients with IBD and to describe the relationship with immunosuppressive therapies and clinical management after tumor diagnosis., Methods: Retrospective, multicenter, observational, 5-year follow-up, cohort study. Relative risk [RR] of cancer in the IBD cohort and the background population, therapeutic strategies, and cancer evolution were analyzed., Results: A total of 145 cancers were diagnosed in 133 of 9100 patients with IBD (global cumulative incidence 1.6% vs 2.4% in local population; RR = 0.67; 95% confidence interval [CI]: 0.57-0.78). Patients with IBD had a significantly increased RR of non-melanoma skin cancer [RR = 3.85; 2.53-5.80] and small bowel cancer [RR = 3.70; 1.23-11.13]. After cancer diagnosis, IBD treatment was maintained in 13 of 27 [48.1%] patients on thiopurines, in 2 of 3 on methotrexate [66.6%], none on anti-TNF-α monotherapy [n = 6] and 4 of 12 [33.3%] patients on combined therapy. Rate of death and cancer remission during follow-up did not differ [p > 0.05] between patients who maintained the treatment compared with patients who withdrew [5% vs 8% and 95% vs 74%, respectively]. An association between thiopurines [p = 0.20] or anti-TNF-α drugs [p = 0.77] and cancer was not found., Conclusions: Patients with IBD have an increased risk for non-melanoma skin cancer and small bowel cancer. Immunosuppresive therapy is not related to a higher overall risk for cancer or worse tumor evolution in patients who maintain these drugs after cancer diagnosis., (Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
44. Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy.
- Author
-
Castaño-Milla C, Chaparro M, Saro C, Barreiro-de Acosta M, García-Albert AM, Bujanda L, Martín-Arranz MD, Carpio D, Muñoz F, Manceñido N, García-Planella E, Piqueras M, Calvet X, Cabriada JL, Botella B, Bermejo F, and Gisbert JP
- Subjects
- Adalimumab, Adult, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Antibodies, Monoclonal, Humanized adverse effects, Crohn Disease complications, Crohn Disease surgery, Cutaneous Fistula etiology, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Rectal Fistula etiology, Retrospective Studies, Severity of Illness Index, Young Adult, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Crohn Disease drug therapy, Cutaneous Fistula drug therapy, Rectal Fistula drug therapy, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Background: Data regarding the effectiveness of adalimumab (ADA) in the treatment of perianal fistula in patients with Crohn's disease (CD) naive to antitumor necrosis factor (TNF) therapy are scarce., Aim: : To assess the effectiveness of ADA in the treatment of perianal fistulas in CD patients naive to anti-TNF therapy., Methods: A retrospective multicenter study was designed. The Fistula Drainage Assessment Index was used to assess the clinical response, and the Van Assche and Ng indexes to classify radiologic response (magnetic resonance imaging)., Results: A total of 46 patients (83% women, 83% complex fistula) were included. At 6 months, 72% of patients responded to ADA (54% remission, 18% partial response) and at 12 months 49% responded (41% remission, 8% partial response). Among patients with complex fistula, the response rate was 66% at 6 months and 39% at 12 months. Nine patients escalated the ADA dose to 40 mg weekly, 6 for partial response and 3 for absence of response. Thirty-three percent of these patients achieved remission after dose escalation. There was a good correlation between clinical and radiologic assessment of response (κ=0.68). In the multivariate analysis, complex fistula was the only predictor of a worse response (hazard ratio 0.083; 95% confidence interval, 0.0009-0.764; P=0.028). Adverse effects were recorded in 11% of patients., Conclusions: ADA was effective for the treatment of perianal fistulas in CD patients naive to anti-TNF drugs. We found a good correlation between clinical and radiologic assessment of therapy response.
- Published
- 2015
- Full Text
- View/download PDF
45. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
- Author
-
Guerra I, Algaba A, Pérez-Calle JL, Chaparro M, Marín-Jiménez I, García-Castellanos R, González-Lama Y, López-Sanromán A, Manceñido N, Martínez-Montiel P, Quintanilla E, Taxonera C, Villafruela M, Romero-Maté A, López-Serrano P, Gisbert JP, and Bermejo F
- Subjects
- Adalimumab, Adolescent, Adult, Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents adverse effects, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Incidence, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases epidemiology, Infliximab, Male, Psoriasis complications, Psoriasis epidemiology, Retrospective Studies, Risk Factors, Spain epidemiology, Young Adult, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized adverse effects, Inflammatory Bowel Diseases drug therapy, Psoriasis chemically induced, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Aim: Anti-tumor necrosis factor (TNF)-alpha agents are widely used for the treatment of both inflammatory bowel disease (IBD) and psoriasis. Psoriatic skin lesions induced by anti-TNF have been described in patients with IBD. We report a case series of psoriasis induced by anti-TNF agents in IBD patients., Methods: Systematic analysis of cases of psoriasis induced by anti-TNF in an IBD patient cohort in tertiary hospitals of Madrid., Results: A total of 21 of 1294 patients with IBD treated with anti-TNF-alpha agents developed drug-induced psoriasis (cumulative incidence 1.62%; 95% CI 1.06%-2.47%): 14 patients with infliximab and 7 with adalimumab; seventeen with Crohn's disease, 4 with ulcerative colitis. The onset of skin lesions varied in a wide range of time (after a mean 13±8 doses). The most frequent site of skin lesions was the limbs (62%) followed by the trunk (48%) and the scalp (43%). The psoriasis phenotypes were plaque psoriasis (57%), scalp (14%), palmoplantar pustulosis (14%), pustular generalized psoriasis (5%), guttate (5%) and inverse (5%). Four patients interrupted the anti-TNF treatment, and that led to the complete regression of lesions in 1 of them. The other 17 patients were maintained on anti-TNF therapy and managed with topical steroids., Conclusion: Psoriatic lesions can be induced by anti-TNF drugs. Plaque psoriasis on the extremities and trunk were the most frequent presentations in our series. Topical steroid treatment is effective in most patients. Anti-TNF discontinuance may be reserved for patients with severe psoriasis or patients without response to topical therapy., (Copyright © 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
46. A combined strategy of SAGE and quantitative PCR Provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer.
- Author
-
Casado E, García VM, Sánchez JJ, Blanco M, Maurel J, Feliu J, Fernández-Martos C, de Castro J, Castelo B, Belda-Iniesta C, Sereno M, Sánchez-Llamas B, Burgos E, García-Cabezas MÁ, Manceñido N, Miquel R, García-Olmo D, González-Barón M, and Cejas P
- Subjects
- Biomarkers, Tumor metabolism, Humans, Neoadjuvant Therapy, Prognosis, Rectal Neoplasms genetics, Rectal Neoplasms mortality, Survival Analysis, Treatment Outcome, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Rectal Neoplasms diagnosis, Rectal Neoplasms therapy
- Abstract
Purpose: Preoperative chemoradiotherapy (CRT) is the treatment of choice for rectal cancer (RC), but half of the patients do not respond, suffer unnecessary toxicities, and surgery delays. We aimed to develop a model that could predict a clinically meaningful response to CRT by using formalin-fixed paraffin-embedded (FFPE) biopsies., Experimental Design: We first carried out an exploratory screening of candidate genes by using SAGE technology to evaluate dynamic changes in the RC transcriptome in selected refractory patients before and after CRT. Next, 53 genes (24 from SAGE and 29 from the literature) were analyzed by qPCR arrays in FFPE initial biopsies from 94 stage II/III RC patients who were preoperatively treated with CRT. Tumor response was defined by using Dworak's tumor regression grade (2-3-4 vs. 0-1). Multivariate Cox methods and stepwise algorithms were applied to generate an optimized predictor of response and outcome., Results: In the training cohort (57 patients), a 13-gene signature predicted tumor response with 86% accuracy, 87% sensitivity, and 82% specificity. In a testing cohort (37 patients), the model correctly classified 6 of 7 nonresponders, with an overall accuracy of 76%. A signature-based score identified patients with a higher risk of relapse in univariate (3-year disease-free survival 64% vs. 90%, P = 0.001) and multivariate analysis (HR = 4.35 95% CI: 1.2-15.75, P = 0.02), in which it remained the only statistically significant prognostic factor., Conclusions: A basal 13-gene signature efficiently predicted CRT response and outcome. Multicentric validation by the GEMCAD collaborative group is currently ongoing. If confirmed, the predictor could be used to improve patient selection in RC studies., (©2011 AACR.)
- Published
- 2011
- Full Text
- View/download PDF
47. Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study.
- Author
-
Nunes T, Barreiro-de Acosta M, Nos P, Marin-Jiménez I, Bermejo F, Ceballos D, Iglesias E, Gomez-Senent S, Torres Y, Ponferrada A, Arevalo JA, Hernandez V, Calvet X, Ginard D, Monfort D, Chaparro M, Manceñido N, Domínguez-Antonaya M, Villalón C, Perez-Calle JL, Muñoz C, Nuñez H, Carpio D, Aramendiz R, Bujanda L, Estrada-Oncins S, Hermida C, Barrio J, Casis MB, Dueñas-Sadornil MC, Fernández L, Calvo-Cenizo MM, Botella B, de Francisco R, Ayala E, and Sans M
- Subjects
- Administration, Oral, Adult, Anti-Inflammatory Agents administration & dosage, Beclomethasone administration & dosage, Drug Administration Schedule, Female, Humans, Male, Remission Induction, Retrospective Studies, Severity of Illness Index, Treatment Outcome, Anti-Inflammatory Agents therapeutic use, Beclomethasone therapeutic use, Colitis, Ulcerative drug therapy
- Abstract
Background: Beclometasone dipropionate (BDP) is a relatively new topically acting oral steroid to treat mild to moderately active ulcerative colitis (UC). We estimate that 20,000 patients have received oral BDP in Spain in the last two years. Our aim was to evaluate the efficacy and safety of oral BDP in clinical practice., Methods: Retrospective and multicenter study that included 434 patients with active UC treated with BDP. The partial Mayo Clinic score (pMS, 0-9) was used to measure disease activity. Remission was defined as post-treatment pMS of 0 or 1; response as a decrease in pMS of 3 points or 2 points and >30%, and failure as lack of remission or response., Results: BDP dose was 5 mg/day in 88% of patients and mean treatment duration was 6.2 weeks. BDP achieved remission in 44.4%, response in 22.3% and failed in 33.2% of patients. Mean pMS decreased from 4.9 ± 1.3 to 2.4 ± 2.3 (p<0.0001). Remission rate was higher in mild and moderate than in severe UC (p<0.043) and tended to be higher in left-sided and extensive UC than in proctitis (p<0.06). Failure was less frequent in patients treated for >4 weeks (p<0.02). Mild adverse events were reported in 7.6% of patients., Conclusion: BDP induces response or remission in two thirds of active UC patients, with a good safety profile. Patients with mild to moderate, left-sided or extensive UC, receiving BDP for more than 4 weeks are most likely to benefit from this treatment., (Copyright © 2010 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.